People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically significant ... which resulted in losses of 17.5% and 2.4%, respectively. In addition, 33.2% of subjects receiving the ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy ... Step Up trial was conducted to test the efficacy of the higher dose, as the current highest dose available is 2.4 ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that while patients on regular Wegovy at 2. ... placebo experienced 2.4% weight loss. The trial involving more than ...